Navigation Links
Nfocus Neuromedical Appoints Robert O'Holla to Head Regulatory
Date:4/30/2009

Accomplished regulatory executive enhances Nfocus device development team.

PALO ALTO, Calif., April 30 /PRNewswire/ -- Endovascular device start-up Nfocus Neuromedical Inc. announced today the appointment of accomplished regulatory executive Robert O'Holla to its leadership team in the role of Vice President of Regulatory Affairs.

"Bob O'Holla brings an unmatched wealth of regulatory and compliance experience to Nfocus, having served 18 of his last 30 years in the industry in the role of Worldwide Vice President of Regulatory Affairs, Medical Devices, for Johnson & Johnson," said President and CEO Martin Dieck. "His disciplined and strategic approach to the product development and approval processes set him apart as a worldwide expert. We are thrilled to welcome him to Nfocus Neuromedical."

O'Holla has an extensive background in the fields of R&D, quality, policy development and compliance, which uniquely position him for the dynamic needs of Nfocus and its next-generation endovascular devices. He chaired the Technology and Regulatory Advisory Committee at AdvaMed, a premier medical technology industry group for 13 years, and was a key figure in the construction of the Medical Device User Fee and Modernization Act of 2002, which amended and refined food and drug law related to medical devices.

"I welcome the challenges and rewards of serving in my new role with Nfocus," noted O'Holla, "as we strive to bring responsible and innovative products and technological solutions to the emerging field of endovascular neurosurgery."

About Nfocus Neuromedical, Inc.

Nfocus is positioning itself to be the world-wide leader in the development of next-generation endovascular neurosurgery solutions (surgery through less-invasive catheter devices). Backed by premier venture investors, the Company is developing revolutionary systems to treat neurovascular disease, including brain aneurysms, that are simple, safe, cost-effective and curative.

Nfocus was incubated at In-Cube Labs and is backed by Oxford Bioscience Partners, Technology Partners and DFJ-ePlanet Ventures. To learn more about the Nfocus Neuromedical development programs focused on providing faster, simpler and more permanent treatment of vascular diseases of the brain and spine, please visit the new Nfocus website at: www.nfocusneuro.com.

For more information about aneurysms and hemorrhagic stroke see: www.strokeassociation.org and www.snisonline.org


'/>"/>
SOURCE Nfocus Neuromedical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
2. Vasogen Appoints Dr. Eldon Smith Chairman
3. DFB Pharmaceuticals Appoints Maxwell Lea to Vice President Business Development and Corporate Finance
4. Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
5. Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board
6. Ventus Medical Appoints John McCutcheon as President and CEO
7. Sinobiopharma, Inc. Appoints New Director of Marketing
8. Yongye Biotechnology Appoints New Chief Financial Officer
9. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
10. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
11. BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... ... (PRWEB) May 16, 2017 , ... ... Chinese Association of Orthopaedic Surgeons (CAOS), long-standing development partners Invibio Biomaterial Solutions, ... interbody spine surgery workshop to help expand knowledge of the implantation of ...
(Date:5/15/2017)... ... May 15, 2017 , ... ... Advanced Lift Contouring Cream, a gravity-shattering cream with a patented formula, clinically proven ... to bring the Advanced Lift Contouring Cream to our already innovative ELEVATE product ...
(Date:5/12/2017)... May 12, 2017  Eli Lilly and Company (NYSE: ... an investigational treatment for the prevention of episodic ... three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) ... monthly migraine headache days compared to placebo at ... results from these three studies bring us one ...
(Date:5/11/2017)... ... 2017 , ... The key to unlocking the cause of Multiple Sclerosis may ... neurological disorder that can rob people of their ability to see, speak, and walk. ... arises from a genetic tendency towards the disease combined with an unidentified environmental trigger. ...
Breaking Biology Technology:
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
Breaking Biology News(10 mins):